Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology CoTPE:6918 +0.40%74 3-Year EBITDA Growth Rate is 33.60% as of Jun. 2026, which is 58% above its 10-year median of 21.20. GuruFocus rates TPE:6918 with a GF Score™ of 74/100 and a GF Value™ of NT$87.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 688 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 79.94% on this metric.
During the past 12 months, A Plus Biotechnology Co's average EBITDA Per Share Growth Rate was 1.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 33.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of A Plus Biotechnology Co was 43.40% per year. The lowest was -25.80% per year. And the median was 21.20% per year.
A Plus Biotechnology Co (TPE:6918) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
A Plus Biotechnology Co 3-Year EBITDA Growth Rate Related Terms
TPE:6918 vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's 3-Year EBITDA Growth Rate falls into.
A Plus Biotechnology Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 33.60% mean?
A Plus Biotechnology Co (TPE:6918) has a 3-Year EBITDA Growth Rate of 33.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for A Plus Biotechnology Co and its competitors. This is 58% above median its historical median of 21.20. According to the industry distribution chart, A Plus Biotechnology Co ranks #138 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 20.1%.
Is A Plus Biotechnology Co's 3-Year EBITDA Growth Rate too high?
A Plus Biotechnology Co's current 3-Year EBITDA Growth Rate of 33.60% is 58% above median its 10-year median of 21.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. A Plus Biotechnology Co's value of 33.60% is 314.8% above this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #138 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #138 out of 688 companies for 3-Year EBITDA Growth Rate. This places A Plus Biotechnology Co in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. A Plus Biotechnology Co's value of 33.60% is 314.8% above this benchmark. While the company's 10-year median is 21.20 vs. the industry median of 8.10, A Plus Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current 3-Year EBITDA Growth Rate of 33.60% is 314.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current 3-Year EBITDA Growth Rate is 33.60%, which is 58% above median its own 10-year median of 21.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.16, compared to a current price of NT$75.20 — trading 13.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 33.60%, which is 58% above median its 10-year median of 21.20 and 314.8% above the Medical Devices & Instruments industry median of 8.10. A Plus Biotechnology Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current 3-Year EBITDA Growth Rate is 33.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$75.20 is trading 13.7% below its estimated GF Value™ of NT$87.16.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
3-Year EBITDA Growth Rate: 33.60% (58% above median its 10-year median of 21.20)
GF Value™: NT$87.16 vs. price of NT$75.20 (13.7% below fair value)
Industry Position: 314.8% above the Medical Devices & Instruments median (#138 of 688)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
74GF Score
Get the complete analysis for TPE:6918
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
